Ionil (Coal Tar Solution)

Coal Tar Solution, the active ingredient in Ionil, is a keratinolytic / antipsoriatic presented as a solution for topical use. It treats psoriasis, seborrheic dermatitis and chronic eczema in patients who need dermatologic therapy and benefit from anti‑inflammatory and keratolytic action.

GNH USA supplies Ionil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ionil (Coal Tar Solution) is used in dermatologic conditions characterized by hyperproliferative and inflammatory skin lesions.

- Psoriasis: reduces scaling, erythema and plaque thickness. - Seborrheic dermatitis: alleviates flaking, redness and itching. - Chronic eczema: improves inflammation, itching and skin barrier function.

Ionil may cause local skin reactions, especially when applied to sensitive areas.

Common Side Effects: - Skin irritation: mild redness or discomfort at the application site. - Dryness: increased skin dryness or scaling. - Itching: transient pruritus after application. - Burning sensation: brief burning feeling on the skin. - Contact dermatitis: localized allergic reaction. - Erythema: mild redness.

Serious or Rare Side Effects: - Severe allergic reaction: swelling, hives or systemic symptoms. - Skin ulceration: deep ulcer formation at the site. - Photosensitivity: heightened sensitivity to sunlight. - Systemic toxicity: rare systemic effects if large areas are treated.

Before using Ionil, consider the following safety measures.

- Pregnancy: safety not established; avoid unless benefits outweigh risks. - Breastfeeding: unknown; assess potential risk to infant. - Children: use only under medical supervision and appropriate dosing. - Application site: apply to intact skin; avoid eyes, mucous membranes and open wounds. - Concomitant irritants: do not combine with other topical irritants or strong chemicals. - Store at room temperature: keep in the original container, protect from light and moisture.

Ionil may interact with other topical agents or systemic therapies.

Major Interactions (Avoid): - Concurrent use with other keratolytic agents (e.g., salicylic acid) may increase skin irritation. - Combination with phototherapy may enhance photosensitivity.

Moderate Interactions (Monitor Closely): - Co‑administration with topical corticosteroids may alter absorption and efficacy. - Use with other topical anti‑inflammatory agents may increase risk of irritation. - Application under occlusive dressings may raise systemic absorption.